Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To investigate the STRoke Interactive Virtual thErapy (STRIVE) intervention on upper-extremity clinical outcomes in community-dwelling stroke survivors.
Design: Assessor-blinded randomized controlled trial.
Setting: Study screening and testing was conducted in a university clinic. Participants completed the virtual therapy (VT) intervention in a community-based stroke support group setting.
Participants: Of 124 stroke survivors initially assessed, 60 participants were recruited (time poststroke, 13.4±8.9 y). Participants were allocated to either VT or control group using a block randomization design and were stratified by sex.
Interventions: Participants were randomized to receive 8 weeks of VT or usual care. The intervention consisted of approximately 45 minutes of twice weekly VT training on the Jintronix Rehabilitation System.
Main Outcome Measures: Between-group differences in the Fugl-Meyer Upper Extremity scale and Action Research Arm Test score were joint primary outcomes in this study.
Results: Significant between-group differences for the Fugl-Meyer Upper Extremity scale were seen at the end of the intervention (F=5.37, P=.02, d=0.41). No significant differences were observed with the Action Research Arm Test. No adverse events were reported.
Conclusions: We demonstrated clinically meaningful improvements in gross upper extremity motor function and use of the affected arm after a VT intervention delivered via a community-based stroke support group setting. This data adds to the contexts in which VT can be used to improve upper limb function. Use of VT in community-based rehabilitation in chronic stroke recovery is supported.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.apmr.2020.03.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhancing Mindfulness-Based Cognitive Therapy in a Virtual Reality: A Prospective Interventional Study.
Sci Rep
September 2025
Department of Data Science, Hanyang University, Seoul, 04763, Republic of Korea.
The increasing prevalence of depression has highlighted Mindfulness-Based Cognitive Therapy (MBCT) as an effective treatment. However, conventional MBCT has several limitations, including barriers to access, the need for trained professionals, and inconsistent levels of participant engagement. The feasibility of using Virtual Reality (VR) for MBCT has emerged as a promising solution, but further research is needed to assess its therapeutic potential.
View Article and Find Full Text PDFComputational fluid dynamics (CFD) modelling of liquid embolic agents (Onyx) used in brain arteriovenous malformation (AVM) treatment to predict the distal penetration behavior.
Med Eng Phys
October 2025
Ansys Inc., Houston, TX 77094, USA.
Introduction: Benchtop and animal models have traditionally been used to study the propagation of Onyx Liquid Embolic Systems (Onyx) used in the treatment of brain arteriovenous malformations (AVM). However, such models are costly, do not provide sufficient detail to elucidate how variations in Onyx viscosity alter flow dynamics, and rely on some trial-and-error, resulting in elongated timelines for product development.
Objectives: The goal of this study was to leverage Computational Fluid Dynamics (CFD) simulations to predict the behavior of different Onyx formulations.
Virtual Reality Distraction vs Nitrous Oxide for Reducing Anxiety and Injection Pain.
Anesth Prog
September 2025
Objective: The purpose of this study was to compare nitrous oxide (N2O) vs virtual reality (VR) as methods for reducing pain and anxiety during a dental injection. The primary objectives were to assess acute changes in stress responses by comparing salivary cortisol levels between the 2 groups and differences in injection pain scores.
Methods: A total of 132 female subjects serving as their own control received maxillary lateral incisor infiltration injections with the use of either N2O or a VR headset during separate appointments spaced at least 2 weeks apart.
High-throughput screening identifies a dual-activity inhibitor of OXCT1 for hepatocellular carcinoma therapy.
Bioorg Chem
September 2025
State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Science and Medicine, University of Science and Technology of China, Hefei 230027, China; Institute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei 230601, China;
3-Oxoacid CoA-transferase 1 (OXCT1) plays a crucial role in hepatocellular carcinoma (HCC) progression through its ketolytic and succinyltransferase activities. Despite its potential as a therapeutic target, no small molecules have been developed to inhibit the dual enzymatic activities of OXCT1 specifically. In this study, our structural analysis revealed that the active sites for both enzymatic functions of OXCT1 are located in the same pocket.
View Article and Find Full Text PDFStructure-guided discovery of nitrobenzo-2-oxa-1,3-diazole (NBD) scaffold-based PFKFB4 inhibitors for cancer therapy.
Eur J Med Chem
August 2025
School of Chemistry and Chemical Engineering, Anhui University of Technology, Ma'anshan, 243032, Anhui, PR China. Electronic address:
Cancer remains a leading global cause of mortality, with treatment efficacy often compromised by drug resistance, highlighting the urgent need for novel targeted therapies. The enzyme fructose-2,6-bisphosphatase 4 (PFKFB4) governs glycolytic flux by modulating fructose-2,6-bisphosphate (F2,6BP) levels. PFKFB4 overexpression has been observed in various cancers and correlates with tumor growth, aggressiveness, and poor prognosis.
View Article and Find Full Text PDF